PMV Pharma appoints new CFO, CMO departs; leadership reshuffled as late-stage program advances

PMV Pharmaceuticals, Inc.

Michael Carulli promoted to CFO; Winston Kung transitions to advisor through March 2024.
Leila Alland steps down as CMO; remains advisor through March 2024 at $500/hour.
Deepika Jalota appointed Chief Development Officer; Marc Fellous named SVP Clinical Development.
Robert Ticktin expands role to include Operations; Tim Smith adds Corporate Development duties.
Carulli receives $370K base salary, 40% bonus target, and severance policy coverage.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Winston Kung

Chief Operating Officer and Chief Financial Officer

PMVP · PMV Pharmaceuticals, Inc.

Effective: 2024-01-04
Successor: Michael Carulli
Filed: January 5, 2024, 6:59 PM ET

On January 5, 2024, the Company also announced that Winston Kung, the Company’s current Chief Operating Officer (“ COO ”) and CFO, will transition from his role as COO and CFO, effective January 4, 2024.

Departed

Leila Alland

Chief Medical Officer

PMVP · PMV Pharmaceuticals, Inc.

Effective: 2024-01-05
Filed: January 5, 2024, 6:59 PM ET

Also on January 5, 2024, the Company announced that Leila Alland, M.D., the Company’s Chief Medical Officer (“ CMO ”), will transition from her role as CMO, effective on January 5, 2024.

Appointed

Michael Carulli

Chief Financial Officer

PMVP · PMV Pharmaceuticals, Inc.

Effective: 2024-01-05
Filed: January 5, 2024, 6:59 PM ET

On January 5, 2024, PMV Pharmaceuticals, Inc. (the “ Company ”) announced the appointment of Michael Carulli as Chief Financial Officer (“ CFO ”), principal financial officer and principal accounting officer of the Company

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Winston Kung changed role as Chief Operating Officer and Chief Financial Officer at PMV Pharmaceuticals, Inc..

Action: transitioned from his role as COO and CFO
Role: Chief Operating Officer and Chief Financial Officer

Exact text from the filing

On January 5, 2024, the Company also announced that Winston Kung, the Company’s current Chief Operating Officer (“ COO ”) and CFO, will transition from his role as COO and CFO, effective January 4, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Leila Alland changed role as Chief Medical Officer at PMV Pharmaceuticals, Inc..

Action: transitioned from her role as CMO
Role: Chief Medical Officer

Exact text from the filing

Also on January 5, 2024, the Company announced that Leila Alland, M.D., the Company’s Chief Medical Officer (“ CMO ”), will transition from her role as CMO, effective on January 5, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Carulli was appointed as Chief Financial Officer at PMV Pharmaceuticals, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On January 5, 2024, PMV Pharmaceuticals, Inc. (the “ Company ”) announced the appointment of Michael Carulli as Chief Financial Officer (“ CFO ”), principal financial officer and principal accounting officer of the Company

View on SEC.gov

PMV Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-003348

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.